Utaroh Motosugi Selected Research

gadolinium ethoxybenzyl DTPA

5/2021	Uptake of gadoxetic acid in hepatobiliary phase magnetic resonance imaging and transporter expression in hypovascular hepatocellular nodules.
3/2021	Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.
1/2020	MRI-based risk factors of hepatocellular carcinoma in patients with chronic liver disease: A prospective observational study.
1/2020	Imaging features of hepatic inflammatory pseudotumor: distinction from colorectal liver metastasis using gadoxetate disodium-enhanced magnetic resonance imaging.
1/2020	Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice.
1/2018	Ring-Like Enhancement of Hepatocellular Carcinoma in Gadoxetic Acid-Enhanced Multiphasic Hepatic Arterial Phase Imaging With Differential Subsampling With Cartesian Ordering.
4/2017	Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan.
2/2017	Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.
1/2017	Contrast Agent-Induced High Signal Intensity in Dentate Nucleus on Unenhanced T1-Weighted Images: Comparison of Gadodiamide and Gadoxetic Acid.
1/2017	Combined gadoxetic acid and gadofosveset enhanced liver MRI for detection and characterization of liver metastases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Utaroh Motosugi Research Topics

Disease

18	Hepatocellular Carcinoma (Hepatoma) 05/2021 - 07/2010
14	Liver Diseases (Liver Disease) 03/2021 - 11/2009
12	Neoplasm Metastasis (Metastasis) 01/2020 - 03/2009
7	Neoplasms (Cancer) 02/2020 - 06/2009
4	Fibrosis (Cirrhosis) 01/2020 - 10/2012
3	Dyspnea (Shortness of Breath) 01/2020 - 01/2015
3	Liver Cirrhosis (Hepatic Cirrhosis) 05/2015 - 10/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 05/2016
2	Hepatitis 05/2015 - 10/2012
2	Body Weight (Weight, Body) 09/2012 - 11/2009
2	Colorectal Neoplasms (Colorectal Cancer) 08/2011 - 03/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 08/2011 - 06/2009
1	Inflammation (Inflammations) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Neuroendocrine Carcinoma 02/2020
1	Acute Cholecystitis 02/2020
1	Plasma Cell Granuloma 01/2020
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Varicose Veins (Varicose Vein) 01/2019
1	Lymphoma (Lymphomas) 01/2018
1	Cholangiocarcinoma 01/2018
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2018
1	Portal Hypertension 11/2016
1	Ascites 11/2016
1	Dehydration (Water Stress) 11/2016
1	Cysts 01/2016
1	Venous Thrombosis (Deep-Vein Thrombosis) 09/2014
1	Atrophy 04/2012
1	Liver Cell Adenoma (Hepatocellular Adenoma) 02/2012
1	Focal Nodular Hyperplasia 02/2012
1	Hemangioma (Angioma) 06/2011
1	Signet Ring Cell Carcinoma 09/2010
1	Adenocarcinoma 09/2010
1	Epidermal Cyst (Sebaceous Cyst) 03/2010

Drug/Important Bio-Agent (IBA)

31	gadolinium ethoxybenzyl DTPA FDA Link 05/2021 - 11/2009
11	Contrast MediaIBA 01/2020 - 07/2010
4	Indicators and Reagents (Reagents)IBA 01/2022 - 05/2016
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 10/2011
4	ferric oxide (iron oxide)IBA 08/2011 - 03/2009
3	Capsules (Microcapsules)IBA 11/2020 - 04/2012
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2014
2	IronIBA 01/2022 - 01/2020
2	GadoliniumIBA 01/2020 - 01/2017
2	gadofosveset trisodium (MS 325)FDA Link 01/2017 - 01/2016
1	ChromatinIBA 02/2020
1	SynaptophysinIBA 02/2020
1	P-30 composite resin (P 30)IBA 01/2020
1	Ferrosoferric Oxide (Magnetite)FDA Link 01/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 12/2018
1	AntigensIBA 12/2018
1	Blood Glucose (Blood Sugar)IBA 12/2018
1	CarbohydratesIBA 12/2018
1	Carcinoembryonic AntigenIBA 12/2018
1	Protons (Proton)IBA 10/2018
1	gadodiamide (Omniscan)FDA Link 01/2017
1	gadobenic acid (gadobenate dimeglumine)FDA Link 04/2016
1	Alanine Transaminase (SGPT)IBA 05/2015
1	Surface Antigens (Surface Antigen)IBA 07/2014
1	Keratins (Keratin)IBA 07/2014
1	Pentetic Acid (DTPA)FDA LinkGeneric 07/2011
1	MucinsIBA 09/2010
1	Eosine Yellowish-(YS) (Eosin)IBA 06/2009
1	Coloring Agents (Dyes)IBA 06/2009
1	Hematoxylin (Haematoxylon)IBA 06/2009

Therapy/Procedure

3	Radiotherapy 01/2018 - 05/2016
1	Cholecystectomy 02/2020
1	Off-Label Use 01/2020
1	Fluid Therapy (Oral Rehydration Therapy) 11/2016
1	Transjugular Intrahepatic Portasystemic Shunt 11/2016
1	Therapeutics 01/2016
1	Drug Tapering 09/2014
1	Hepatectomy 06/2013
1	Gastrectomy 11/2009